Mankind Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹54.33₹46.35₹49.28₹47.75₹32.00
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹54.24₹46.28₹49.19₹47.68₹32.00
₹394.87₹394.87₹347.37₹233.73₹185.61
₹372.54₹345.87₹295.87₹257.99₹218.41
—₹75.61₹58.49₹53.73₹45.27
₹57.75₹57.75₹45.89₹44.19₹24.49
—₹1.00₹0.00₹0.00₹0.00
41.341.341.340.140.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹1.03L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS32.0047.7549.2846.3554.33
Diluted EPS32.0047.6849.1946.2854.24
Book Value per Share185.61233.73347.37394.87394.87
Revenue per Share218.41257.99295.87345.87372.54
Cash Flow per Share45.2753.7358.4975.61—
Free Cash Flow per Share24.4944.1945.8957.7557.75
Dividends per Share0.000.000.001.00—
Shares Outstanding (cr)40.140.141.341.341.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.